Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

551 results about "Severe anaemia" patented technology

Severe Anemia. Anemia is a lack of blood, specifically red blood cells. The deficiency of red blood cells and hemoglobin reduces the oxygen-carrying capacity of blood, causing pallor, fatigue, weakness, or shock. Causes of anemia include excessive blood loss from internal bleeding or trauma, destruction of red blood cells by disease,...

Methods and compositions for the treatment and management of hemoglobinopathy and anemia

The present invention is directed to the use of immunomodulatory compounds, particularly members of the class of compounds known as IMiDs™, and more specifically the compounds 4-(Amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione and 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione, to induce the expression of fetal hemoglobin genes, genes essential for erythropoiesis, and genes encoding alpha hemoglobin stabilizing protein, within a population of CD34+ cells. These compounds are used to treat hemoglobinopathies such as sickle cell anemia or β-thalassemia, or anemias caused by disease, surgery, accident, or the introduction or ingestion of toxins, poisons or drugs.
Owner:SIGNAL PHARMA LLC

Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood

The present invention relates to hematopoietic stem and progenitor cells of neonatal or fetal blood that are cryopreserved, and the therapeutic uses of such stem and progenitor cells upon thawing. In particular, the present invention relates to the therapeutic use of fetal or neonatal stem cells for hematopoietic (or immune) reconstitution. Hematopoietic reconstitution with the cells of the invention can be valuable in the treatment or prevention of various diseases and disorders such as anemias, malignancies, autoimmune disorders, and various immune dysfunctions and deficiencies. In another embodiment, fetal or neonatal hematopoietic stem and progenitor cells which contain a heterologous gene sequence can be used for hematopoietic reconstitution in gene therapy. In a preferred embodiment of the invention, neonatal or fetal blood cells that have been cryopreserved and thawed can be used for autologous (self) reconstitution.
Owner:PHARMASTEM THERAPEUTICS

Prognostic, diagnostic, and cancer therapeutic uses of FANCI and FANCI modulating agents

Disclosed herein are methods and compositions for the treatment of cancer. In particular, the present invention identifies and characterizes the FANCI polypeptide as a vital component of the Fanconi anemia pathway and discloses inhibitors of FANCI and methods of using same. Such inhibitors are useful in inhibiting DNA damage repair and can be useful, for example, in the treatment of cancer.
Owner:DANA FARBER CANCER INST INC +2

Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood

The present invention relates to hematopoietic stem and progenitor cells of neonatal or fetal blood that are cryopreserved, and the therapeutic uses of such stem and progenitor cells upon thawing. In particular, the present invention relates to the therapeutic use of fetal or neonatal stem cells for hematopoietic (or immune) reconstitution. Hematopoietic reconstitution with the cells of the invention can be valuable in the treatment or prevention of various diseases and disorders such as anemias, malignancies, autoimmune disorders, and various immune dysfunctions and deficiencies. In another embodiment, fetal or neonatal hematopoietic stem and progenitor cells which contain a heterologous gene sequence can be used for hematopoietic reconstitution in gene therapy. In a preferred embodiment of the invention, neonatal or fetal blood cells that have been cryopreserved and thawed can be used for autologous (self) reconstitution.
Owner:PHARMASTEM THERAPEUTICS

Heterocyclic compounds and their uses

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.
Owner:AMGEN INC

Reduced side-effect hemoglobin compositions

The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.
Owner:BAXTER INT INC +1

Antibodies which activate an erythropoietin receptor

Antibodies and fragments thereof which activate an erythropoietin receptor and stimulate erythropoiesis are described. Also described are hybridoma cell lines which produce the antibodies and methods and compositions for the treatment of anemia.
Owner:AMGEN INC

Heterocyclic compounds and their uses

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on or associated with pi 105 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.
Owner:AMGEN INC

Isoquinolone compound and application thereof

The invention relates to an isoquinolone compound and application thereof. The invention in particular relates to an isoquinolone compound used as a HIF prolyl hydroxylase inhibitor (HIF-PHI) and a pharmaceutical composition thereof. Moreover, the present invention provides the application of the isoquinolinone compound or the pharmaceutical composition thereof in the preparation of a medicament for preventing or treating HIF-associated or HIF-mediated diseases as anemia or ischemia, local ischemia or hypoxia.
Owner:SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD

Iron dextrin compounds for the treatment of iron deficiency anaemia

An iron-dextrin compound for treatment of iron deficiency anaemia comprising hydrogenated dextrin having a weight average molecular weight equal to or less than 3,000 Dalton and a number average molecular weight equal to or higher than 400 Daltons, in stable association with ferric oxyhydroxide. As the molecular weight of the dextrin must be narrow it is another important feature of the invention that the 10% fraction of the dextrins having the highest molecular weight has an average molecular weight of less than 4500 Daltons, and that 90% of the dextrins are having molecular weights of less than 3000 Daltons. It is further important that the 10% fraction having the lowest molecular weight has a weight average molecular weight of 340 Daltons or more.
Owner:PHARMACOSMOS HLDG

Novel Pyrimidine- And Triazine-Hepcidine Antagonists

The present invention relates to new hepcidin antagonists, pharmaceutical compositions containing them and the use thereof as a drug, in particular for the treatment of iron metabolism disorders such as, in particular, iron deficiency diseases and anaemia, in particular anaemia associated with chronic inflammatory disease (ACD: anaemia of chronic disease and AI: anaemia of inflammation).
Owner:VIFOR INT AG

Substituted triazine phenyl urea derivatives and application thereof

The invention relates to substituted triazine phenyl urea derivatives and application of the derivatives used as protein kinases, especially as Raf-1 inhibitors. The compounds provided by the invention can be used for treating various disorders and diseases, especially the protein-kinase-related diseases such as cancers, miocardial infarction, cerebral thrombosis, anaemia, hepatitis C (HCV) and other diseases.
Owner:ZHEJIANG HISUN PHARMA CO LTD

L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof

A compound of ferrous L-threonate with structure (I), its compostions and methods useful for iron supplementation for mammals, particularly for human body to improve and treat nutritional iron-deficiency anemia, blood loss anemia and hemolytic anemia.
Owner:JUNENG INDUSTRY CO LTD

Neuroprotective iron chelators and pharmaceutical compositions comprising them

Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, eg. a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, a inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding ageing, and prevention and / or treatment of skin ageing and skin protection against sunlight and / or UV light. The iron chelator function is provided by a 8-hydroxyquinoline, a hydroxypyridinone or a hydroxamate moiety, the neuroprotective function is imparted to the compound e.g. by a neuroprotective peptide, and a combined antiapoptotic and neuroprotective function by a propargyl group.
Owner:TECHNION RES & DEV FOUND LTD +1

Spleen polypeptide extract, its preparing process and use

ActiveCN1634987AThe preparation process is stable and matureImprove malignant transformationAntibacterial agentsPowder deliveryImmunomodulatory drugSecondary immune deficiency
The invention discloses a spleen polypeptide extract extracted from the spleen tissue of mammals other than humans. The mammalian tissue is subjected to fat removal, homogenization, acid adjustment, freezing and thawing, pH adjustment, precipitation, heating, and centrifugation. Filtration, ultrafiltration and other steps to obtain the spleen polypeptide extract; the drug is an immunomodulatory drug that can improve and improve the immune function of the body, and can be used for primary and secondary cellular immune deficiency diseases (such as eczema, thrombocytopenia, multiple Infection syndrome, etc.), respiratory tract and lung infection, habitual cold, chronic hepatitis B, mumps, recurrent aphtha and other diseases, can be used in the treatment of leukopenia, leukemia, aplastic anemia caused by radiotherapy and chemotherapy , Lymphoma and other malignant tumors, to improve the malignant transformation of tumor patients, to improve postoperative or critically ill patients when they are weak.
Owner:融致丰生制药有限公司

Iron supplement composition, its preparing method and application of the same

The invention discloses a pharmaceutical composition as an iron supplement agent, which comprises ferrous glycinate, antioxidant and medicinal carrying agents. The invention also discloses preparations containing the composition, the process for preparing the composition and the preparations, and the use of the composition in preventing and treating iron deficiency. The composition is capable of appreciably improving the absorption ratio of iron in intestinal tract, thereby improving iron-deficiency anemia effectively.
Owner:内蒙古百金纳投资有限责任公司 +1

Spleen extracts, its preparation method and use

ActiveCN1765371AThe preparation process is stable and matureImprove malignant transformationPowder deliveryPeptide/protein ingredientsDiseaseWhite blood cell
The invention discloses a spleen extract prepared from mammalsí» spleens through fat-removing, homogenating, comminuting, settling and hyperfiltrating, and comprises the following constituents: polypeptides, free amino acid, nucleic acid and total sugar. The spleen extract can be used for preparing medicament for the treatment of cell immunodeficiency diseases, respiratory tract and lung infection, chronic hepatitis B, mumps, aphtae, leucopenia, leukemia, regenerative anemia, and malignant tumour.
Owner:融致丰生制药有限公司

Fluorinated 4-azasteroid derivatives as androgen receptor modulators

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and / or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP

Mobilization of hematopoietic cells

Improved methods and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as Rac1 and Rac2 alone or in combination. Specifically, methods are disclosed for mobilizing hematopoietic stem cells into a subject's peripheral blood. In particular, embodiments of the method involve inhibition of both Rac1 and Rac2 GTPases to increase the numbers of hematopoietic stem cells into a subject's peripheral blood of a subject. The subject's blood can be processed and used to repopulate the destroyed lymphohematopoietic system of a recipient and may in the future be utilized to repair a variety of non-hematopoietic tissues. Therefore, hematopoietic stem cells mobilized into a subject's peripheral blood by the method of the invention is useful as a source of donor cells in bone marrow transplantation for the treatment of a variety of disorders, including cancer, anemia, autoimmunity and immunodeficiency. They can also be used for increasing white blood cell survival and for chemotherapy.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI

L-aspartic acid for the treatment of assorted health problems

A method of treating or preventing one's health problem that are associated with one's cells having a poor metabolic capability to process fat includes ingesting a therapeutically effective dosage of an anaplerotic precursor. Examples of such health problems include obesity and the related health conditions that are aggravated by obesity, diabetes, hypertension, atherosclerosis, migraines and headaches, menstrual cramps, cholesterol excesses, multiple sclerosis and Alzheimer's disease, anemia, high blood uric acid levels, ketosis, tobacco and other drug addictions, and digestive problems. In a preferred embodiment, this method includes the daily ingestion of L-aspartic acid, or a pharmaceutically acceptable analog thereof, at the rate of 10-14 g / day and restricting from one's diet the intake of starchy foods.
Owner:INST DEL METABOLISMO CELULAR

Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments

The present invention relates to administration of milk fat or a milk fat analogue, optionally with at least one additional therapeutic factor, preferably lactoferrin or metal ion lactoferrin, preferably iron lactoferrin, preferably bovine lactoferrin, preferably iron bovine lactoferrin, or a metal ion functional variant or functional fragment thereof, to inhibit tumour formation or growth, maintain or improve one or more of the white blood cell count, the red blood cell count, or the myeloid cell count, reduce cachexia, mucositis, and anemia, stimulate the immune system and treat or prevent cancer and the symptoms of cancer and side-effects of cancer therapies. The methods and medicinal uses of the invention may be carried out by employing dietary (as foods or food supplements), nutraceutical or pharmaceutical compositions. Compositions useful in the methods of the invention are also provided.
Owner:FONTERRA COOP GRP LTD

Heterocyclic compounds and their uses

InactiveUS20130079342A1Organic active ingredientsSenses disorderB-cell acute lymphoblastic leukaemiaAutoimmune disease
Substituted bicyclic heteroaryls of the following formulae and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.
Owner:AMGEN INC

Compositions and methods for treating anemia

PendingUS20160143891A1Raise serum hemoglobinRiskHeavy metal active ingredientsBiocideDosing regimenNephrosis
Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.
Owner:AKEBIA THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products